EMA CHMP recommends AbbVie’s mirvetuximab soravtansine for ovarian cancer
The treatment targets those with folate receptor alpha (FRα)-positive, platinum-resistant, and high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone one to three treatment